Chicago, May 2024 — miRecule, a cutting-edge startup focused on developing antibody RNA conjugate therapeutics, clinched the top spot at the prestigious MedCity INVEST Biopharma track competition held at the Ritz Carlton in Chicago. The event, presented by MedCity News and the Mid-America Healthcare Investors Network (MHIN), brought together active investors and promising entrepreneurs from the healthcare industry.
miRecule’s innovative approach to personalized RNA therapeutics captured the attention of venture capital judges, who recognized the company’s potential to revolutionize healthcare.
“We’re delighted to be recognized by industry experts,” said Dave Lemus, COO/CFO of miRecule. “Moreover we are very pleased miRecule’s innovative RNA-based approach in tackling head and neck cancer with its product MC-30 has been acknowledged for its potential to address a clear unmet medical need in these patients”
MedCity INVEST has a long-standing tradition of uniting investors with startups in biopharma, diagnostics, medical devices, and health tech. This victory marks another milestone for miRecule as it continues to drive innovation in RNA-based precision medicine.
Read more: Here’s Why VC Judges Chose These 4 Startups as INVEST Pitch Perfect Winners